Bibliography
- Iwamoto J, Takeda T, Sato Y, Effects of risedronate on osteoarthritis of the knee. Yonsei Med J 2010;51:164-70
- Schnitzer TJ, Ballard IM, Constantine G, Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumeton in patients with active osteoarthritis of the knee. Clin Ther 1995;12:602-12
- Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56
- Shen H, Sprott H, Aeschlimann A, Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology (Oxf) 2006;45:765-70
- Cha HS, Koh JH, Jeon CK, Comparison of the efficacy and safety of naproxen CR and nabumeton in the treatment of patients with osteoarthritis of the knee. Int J Clin Pharmacol Ther 2001;39:539-45
- Schnitzer TJ, Beier J, Geusens P, Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;51:549-57
- Liang TH, Hsu PN. Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. Curr Med Res Opin 2003;19:336-41
- Hirate K, Uchida A, Ogawa Y, Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res 2006;54:288-94
- Okamoto T. NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications of NSAIDs (Review). Int J Mol Med 2002;9:369-72
- Tang HB, Inoue A, Oshita K, Zaltoprofen inhibits bradykinin-induced responses by blocking the activation of second messenger signaling cascades in rat dorsal root ganglion cells. Neuropharmacology 2005;48:1035-42
- Matsumoto M, Inoue M, Ueda H. NSAID zaltoprofen possesses novel anti-nociceptive mechanism through blockage of B2-type bradykinin receptor in nerve endings. Neurosci Lett 2006;397:249-53
- Wagenitz A, Mueller EA, Frentzel A, Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenac's use in this patient population. Curr Med Res Opin 2007;23:1957-66
- Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15
- Altman R, Brandt K, Hochberg M, Design and conduct of clinical trials in patients with osteoarthritis: recommendation from the task force of the Osteoarthritis Research Society: results from a workshop. Osteoarthritis Cartilage 1996;4:217-43
- Angst F, Aeschlimann A, Steiner W, Responsiveness of the WOMAC osteoarthritis index as compared to SF-36 in patients with osteoarthritis of the legs undergoing comprehensive rehabilitation intervention. Ann Rheum Dis 2001;60:834-40
- Tsurumi K, Kyuki K, Yanagihara M, Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid. 5th communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite. Arzneimittelforschung 1986;36:1818-22
- Pareek A, Chandanwale AS, Oak J, Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac – an Indian experience. Curr Med Res Opin 2006;22:977-88